CBIO

Crescent Biopharma, Inc.

$13.92

1.98%

SectorHealthcareIndustryBiotechnologyCountryUnited States

Overview AI Brief ChartChart & Performance Financials ExposureRevenue Exposure FilingsFilings & Red Flags ScoresScores & Valuation News Analysts InsidersInsiders & Short Interest Ownership

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Source: Yahoo Finance

Market Cap$517.1M

Dividend Yield0.00%

AnalystsStrong Buy+126.3% target

Beta1.23

AI summary

Price & performance

1M-19.0%

3M-20.9%

YTD+18.9%

1Y+4.1%

52-week range—

Beta1.23

Full chart and returns against a benchmark

Q-Score

42/ 100

Quality against peers; 50 is the peer median.

Growth—

Risk33

Performance42

Valuation36

Profitability—

Leverage80

Sentiment95

Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$10.8M

Net income-$153.9M

Net margin—

Historical fundamentals

Red flags in filings

1active red flag

Auditor changeJun 18, 2025

Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

CBIOIndustryP/E—89.69P/S43.5111.88EV/EBITDA—67.10P/B3.176.22PEG—4.02

Dividend yield0.00%

Every valuation metric

Historical Fundamentals

Revenue

Net Income

Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.

Latest Results

The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.

Metric	FY 2025	vs a year before	Q2 2026	vs a year before
Revenue	$10.8M	—	$0.00	—
Net Income	-$153.9M	—	-$24.8M	—

Q-Scores

OverallCombines the categories below, except Sentiment

Industry 5742

Risk

Industry 5533

Performance

Industry 6642

Valuation

Industry 2536

Leverage

Industry 6880

Sentiment

Industry 6095

Key Metrics

Fundamentals: trailing twelve months to Jun 2026, from the latest 10-K and 10-Qs.

Market Beta (5-factor)

IM 0.72SM 0.781.08

Market Cap

517.1M

Dividend Yield

IM 0.00%SM 0.00%0.00%

Volume

IM 693.1KSM 741.7K343.9K

Industry Market Share

0.04%

Sector Market Share

0.01%

IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.

Comparable Companies

The companies closest in size in Biotechnology (filled from its sector when there are few), with the median and rank across all 571 in the industry.

Company	Market cap	P/S	P/B	FCF yield	Implied growth	Revenue growth	Op. margin	ROE	Debt/equity
CBIOCrescent Biopharma, Inc.	$517.1M	43.5	3.2	-14.2%	—	—	—	-101.1%	0.0
CAPRCapricor Therapeutics, Inc.	$515.7M	—	2.1	-22.3%	—	—	—	-52.6%	0.0
DMACDiaMedica Therapeutics Inc.	$521.5M	—	13.6	-6.0%	—	—	—	-97.9%	0.0
RGNXREGENXBIO Inc.	$508.5M	3.3	3.4	-30.4%	—	-4.6%	-95.7%	-118.4%	0.0
NGNENeurogene Inc.	$505.9M	—	1.4	-19.3%	—	—	—	-33.6%	0.0
EPRXEupraxia Pharmaceuticals Inc.	$504.1M	—	6.1	-5.8%	—	—	—	-47.0%	0.0
STTKShattuck Labs, Inc.	$493.9M	—	2.6	-10.1%	—	—	—	-35.0%	0.0
MDXGMiMedx Group, Inc.	$491.8M	1.6	2.3	3.9%	5.3%	-22.8%	-8.3%	-9.1%	0.0
OVIDOvid Therapeutics Inc.	$546.8M	—	2.6	-10.0%	—	-76.2%	—	-16.4%	0.0
Industry median		7.7	2.2	-22.3%	9.9%	12.8%	-76.9%	-60.8%	0.0
CBIO percentile		82nd	61st	60th	—	—	—	32nd	39th